These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 26923554)
1. Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer. Kang CH; Kim EY; Kim HR; Lee CO; Lee HK; Jeong HG; Choi SU; Yun CS; Hwang JY; Lee JY; Son YH; Ahn S; Lee BH; Jung H; Park CH Cancer Lett; 2016 May; 374(2):272-8. PubMed ID: 26923554 [TBL] [Abstract][Full Text] [Related]
2. Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins. Kang CH; Yun JI; Lee K; Lee CO; Lee HK; Yun CS; Hwang JY; Cho SY; Jung H; Kim P; Ha JD; Jeon JH; Choi SU; Jeong HG; Kim HR; Park CH Biochem Biophys Res Commun; 2015 Aug; 464(3):762-7. PubMed ID: 26168728 [TBL] [Abstract][Full Text] [Related]
3. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809 [TBL] [Abstract][Full Text] [Related]
4. ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment. Lee HJ; Latif M; Choe H; Ali I; Lee HK; Yang EH; Yun JI; Chae CH; Jung JK; Kim HR; Lee CO; Park CH; Lee K Arch Pharm Res; 2014; 37(9):1130-8. PubMed ID: 24446111 [TBL] [Abstract][Full Text] [Related]
5. Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment. Park CH; Choe H; Jang IY; Kwon SY; Latif M; Lee HK; Lee HJ; Yang EH; Yun JI; Chae CH; Cho SY; Choi SU; Ha JD; Jung H; Kim HR; Kim P; Lee CO; Yun CS; Lee K Bioorg Med Chem Lett; 2013 Nov; 23(22):6192-6. PubMed ID: 24095090 [TBL] [Abstract][Full Text] [Related]
6. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400 [TBL] [Abstract][Full Text] [Related]
7. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib. Radaram B; Pisaneschi F; Rao Y; Yang P; Piwnica-Worms D; Alauddin MM Eur J Med Chem; 2019 Nov; 182():111571. PubMed ID: 31425908 [TBL] [Abstract][Full Text] [Related]
8. Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. Mathi GR; Kang CH; Lee HK; Achary R; Lee HY; Lee JY; Ha JD; Ahn S; Park CH; Lee CO; Hwang JY; Yun CS; Jung HJ; Cho SY; Kim HR; Kim P Eur J Med Chem; 2017 Jan; 126():536-549. PubMed ID: 27915169 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor. Kang GA; Lee M; Song D; Lee HK; Ahn S; Park CH; Lee CO; Yun CS; Jung H; Kim P; Ha JD; Cho SY; Kim HR; Hwang JY Bioorg Med Chem Lett; 2015 Sep; 25(18):3992-8. PubMed ID: 26235945 [TBL] [Abstract][Full Text] [Related]
10. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Kort A; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH Pharmacol Res; 2015 Dec; 102():200-7. PubMed ID: 26361725 [TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428 [TBL] [Abstract][Full Text] [Related]
12. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343 [TBL] [Abstract][Full Text] [Related]
13. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC. Chen Y; Wu J; Wang A; Qi Z; Jiang T; Chen C; Zou F; Hu C; Wang W; Wu H; Hu Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Liu Q; Liu J Eur J Med Chem; 2017 Oct; 139():674-697. PubMed ID: 28850922 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and anticancer activities of ceritinib analogs modified in the terminal piperidine ring. Wang P; Cai J; Chen J; Ji M Eur J Med Chem; 2015 Mar; 93():1-8. PubMed ID: 25644671 [TBL] [Abstract][Full Text] [Related]
15. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase. Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P Drug Metab Dispos; 2015 Jan; 43(1):54-62. PubMed ID: 25349124 [TBL] [Abstract][Full Text] [Related]
16. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Sakamoto H; Tsukaguchi T; Hiroshima S; Kodama T; Kobayashi T; Fukami TA; Oikawa N; Tsukuda T; Ishii N; Aoki Y Cancer Cell; 2011 May; 19(5):679-90. PubMed ID: 21575866 [TBL] [Abstract][Full Text] [Related]
18. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer. Ni Z; Zhang TC J Mol Model; 2015 Jul; 21(7):175. PubMed ID: 26084268 [TBL] [Abstract][Full Text] [Related]
19. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728 [TBL] [Abstract][Full Text] [Related]
20. Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives. Guo M; Zuo D; Zhang J; Xing L; Gou W; Jiang F; Jiang N; Zhang D; Zhai X Eur J Med Chem; 2018 Oct; 158():322-333. PubMed ID: 30223120 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]